| CTNT 0.1608 -5.80% | ZSPC 0.0871 21.48% | ONFO 1.5 124.89% | MYSE 3.3 129.17% | NVDA 198.35 -0.26% | BITO 10.35 0.49% | TZA 5.43 -0.46% | TSLL 13.07 -1.73% | INTC 68.5 5.48% | CAPS 0.5345 -9.25% | HUBC 0.1833 -29.50% | DVLT 0.8375 19.63% | SOXS 20.28 -3.13% | TQQQ 56.43 1.40% | QBTS 21.505 3.34% | AGAE 0.5219 10.57% | HIMS 26.99 11.12% | IONQ 44.68 3.31% | DGNX 0.5556 -0.79% | GRAB 4.02 2.55% | SNAP 6.02 -0.33% | SOFI 19.03 1.28% | SMR 11.41 -2.56% | TSLA 388.9 -0.78% | ITP 0.2 -3.57% | BMNG 1.53 0.66% | SOXL 88.37 2.80% | AMD 278.26 7.80% | RGTI 19.45 1.78% | OPEN 5.27 9.34% | MDCX 0.3003 -0.60% | PLUG 2.86 -2.39% | MARA 11.55 10.32% | NVD 5.81 0.69% | AAL 12.27 0.82% | SQQQ 58.61 -1.40% | IMMP 0.5796 6.54% | HOOD 86.85 -0.54% | ONDS 10.2 1.69% | NVTS 12.37 20.57% | RMSG 2.55 42.46% | BYND 0.782 4.11% | NOK 10.29 3.00% | NFLX 107.79 0.07% | ORCL 178.46 5.09% | SPY 701.66 0.25% | SOUN 7.7 -1.91% | AAPL 263.4 -1.14% | PBM 5.87 103.82% | PLTR 142.76 0.43%

Pfizer Raises Profit Forecast After Q2 Earnings Beat

Pfizer (NYSE:PFE) posted better-than-expected second-quarter earnings and revenue and raised its full-year profit outlook, sending shares up over 4% intra-day.

The pharmaceutical giant reported earnings per share of $0.78 for the quarter, ahead of the $0.57 consensus. Revenue rose 10% year-over-year to $14.7 billion, also topping estimates of $13.47 billion.

Chairman and CEO Dr. Albert Bourla said the quarter reflected strong execution, commercial progress, and pipeline advancement. The company cited margin improvement, lower tax rates, and favorable currency moves as drivers of the revised forecast.

Pfizer raised its full-year adjusted EPS guidance to a range of $2.90–$3.10, up $0.10 at the midpoint. The company maintained its full-year revenue forecast of $61.0 billion to $64.0 billion.

Published on: August 5, 2025